The effect of aldosterone antagonists for ventricular arrhythmia: A meta-analysis

Clinical Cardiology

Volumn 33, Issue 9, 2010, Pages 572-577

  Wei, Jiafu ^a   Ni, Juan ^a   Huang, Dejia ^a   Chen, Mao ^a   Yan, Shaodi ^a   Peng, Yong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE; MAGNESIUM; PLACEBO; POTASSIUM; SPIRONOLACTONE;

ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAGNESIUM BLOOD LEVEL; META ANALYSIS; POTASSIUM BLOOD LEVEL; RISK REDUCTION; SUDDEN DEATH; SYSTEMATIC REVIEW;

ALDOSTERONE ANTAGONISTS; CONFIDENCE INTERVALS; DEATH, SUDDEN, CARDIAC; DIURETICS; HUMANS; RISK; SPIRONOLACTONE;

EID: 77956910160     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20762     Document Type: Article

References (25)

1. Yap YG, Duong T, Bland M, et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J. 2005;26:1385-1393.
2. Drögemüller A, Seidl K, Schiele R, et al. Prognostic value of non-sustained ventricular tachycardias after acutemyocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats. Z Kardiol. 2003;92:164-172.
3. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;7:12A-16A.
4. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention ofmyocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
5. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
6. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033.
7. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80-85.
8. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
9. Beck L, Blanc-Guillemaud V, Cherif OK, et al. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology. 2001;96:85-93.
10. Yang SS, Han W, Zhou HY, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl). 2008;121:38-42.
11. De Mello WC. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst. 2006;7:40-46.
12. Stambler BS, Laurita KR, Shroff SC, et al. Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm. 2009;6:776-783.
13. Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534-541.
14. Cittadini A, Monti MG, Isgaard J, et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res. 2003;58:555-564.
15. Pitt B, Zannad F, Remme WJ, et al; for Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
17. Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail. 2007;13:170-177. (Pubitemid 46591953)
18. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
19. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-1211.
20. Shah NC, Pringle SD, Donnan PT, et al. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens. 2007;25:2345-2351.
21. Skvortsov AA, Mareev V, Orlova Ia A, et al. Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy[in Russian]. Kardiologiia. 2008;48:52-64.
22. Anand K, Mooss AN, Mohiuddin SM. Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. J Renin Angiotensin Aldosterone Syst. 2006;7:15-19. (Pubitemid 43891240)
23. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.
24. Muto T, Ueda N, Opthof T, et al. Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2007, 293: H2710-2718.
25. Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, et al. Magnesium and cardiovascular drugs: interactions and therapeutic role. Ann Ital Med Int. 1999;14:40-45. (Pubitemid 29148741)